The U.S. Food and Drug Administration has approved Pfizer Inc.'s (NYSE: PFE) Ibrance (palbociclib) in combination with trastuzumab, with or ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE